Eric D. Malek, MBAVice President of Corporate Development |
Eric Malek joined Threshold as the Vice President, Corporate Development in 2010. He will lead business development, strategy and planning with an initial focus on partnering the Company's clinical stage hypoxia activated prodrug, TH-302. Prior to joining Threshold he led corporate development at BiPar Sciences where he initiated the partnering effort that led to the $500 million acquisition by Sanofi-Aventis. Prior to BiPar, Mr. Malek was Vice President, Corporate Development at Allos Therapeutics, where he led the acquisition and product planning efforts for FOLOTYN TM, recently approved by the FDA for relapsed or refractory peripheral T-cell lymphoma. Before Allos, Mr. Malek held business development positions at Gilead Sciences, NeXstar Pharmaceuticals and Ilex Oncology as well as research positions at Janssen Pharmaceutica. Eric received a B.A. in Biochemistry from the University of Arizona and an M.B.A. from the University of Michigan.
